Literature DB >> 7900702

Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy.

V Coen1, M Van Lancker, W De Neve, G Storme.   

Abstract

By means of a retrospective study an evaluation was made of prognostic factors on survival in patients with inoperable locoregional non-small cell lung cancer. The study was performed on a group of 239 patients with a median age of 69 years, 225 men, and 14 women. Patients were treated with external radiotherapy without (184) or with (55) chemotherapy. They received either continuous-course radiotherapy (5,500 cGy in 27-28 fractions and 5.5 weeks) or split-course radiotherapy (1 series of 3,000 cGy, 2 series of respectively 3,000 cGy and 2,500 cGy, or 3 series of, respectively 3,000 cGy, 2,500 cGy, and 2,000 cGy; each series in 10 fractions and 2 weeks, separated by a 4-week interval). Univariate analysis was done by life-table analysis and log-rank test, multivariate analysis by the Cox Proportional Hazards model. The overall survival at 1, 2, and 3 years was 36%, 11%, and 4%. Survival was not significantly influenced by localization of the tumor, grading, distance to the carina, growth pattern, diameter, partial or total atelectasis, lymph node invasion or stage. No significant difference in survival was found between patients who received only radiotherapy and those treated with a combination of radiotherapy and chemotherapy. Univariate analysis showed significant better survival in patients with squamous cell epithelioma, patients without pleural effusion, patients younger than 75 years and patients receiving higher radiation doses. Multivariate analysis showed dose of radiation (P < .001) and pleural effusion (P = .03) to be independent prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900702     DOI: 10.1097/00000421-199504000-00004

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  A practical prognostic index for inoperable non-small-cell lung cancer.

Authors:  T Wigren; H Oksanen; P Kellokumpu-Lehtinen
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

3.  Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma.

Authors:  Yilmaz Bulbul; Bulent Eris; Asim Orem; Ayhan Gulsoy; Funda Oztuna; Tevfik Ozlu; Savas Ozsu
Journal:  Ups J Med Sci       Date:  2010-08       Impact factor: 2.384

Review 4.  Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis.

Authors:  Yuan Yang; Juan Du; Yi-Shan Wang; Han-YuJie Kang; Kan Zhai; Huan-Zhong Shi
Journal:  Clin Transl Sci       Date:  2022-03-21       Impact factor: 4.438

5.  In 18F-positron emission tomography/computed tomography-guided precision radiotherapy for centrally located non-small cell lung cancer, tumor related atelectasis is a prognostic factor of survival.

Authors:  Nan Wang; Yun Qiao; Yingqiu Song; Zheng Wang; Xia Li; Chengsen Liu; Ye Wang; Yu Wu; Rong He; Chenyu Wang; Yangwu Ren; Guang Li; Tianlu Wang
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.